Zuzana Justinova

Zuzana Justinova

Auto-generated profile, based on publicly available information

Zuzana Justinova

Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2007 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PCPaulina Carriba
Paulina Carriba
OOOskar Ortiz
Oskar Ortiz
KPKshitij Patkar
Kshitij Patkar
ZJZuzana Justinova
Zuzana Justinova
JSJessica Stroik
Jessica Stroik
SFSergi Ferre
Sergi Ferre

12 May 2006 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MSMarcello Solinas
Marcello Solinas
ZJZuzana Justinova
Zuzana Justinova
SGSteven R. Goldberg
Steven R. Goldberg
GTGianluigi Tanda
Gianluigi Tanda
Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer‐lasting synthetic analog methanandamide, increase the extracellular dopamine levels in the nucleus accumbens shell of awake, freely moving rats, an effect characteristic of most drugs abused by humans. Anandamide produced two distinctly different effects on dopamine levels: (1) a rapid, transient increase that was blocked by the cannabinoid CB1receptor antagonist rimonabant, but not by the vanilloid VR1receptor antagonist capsazepine, and was magnified and prolonged by the fatty acid amide hydrolase (FAAH) enzyme inhibitor, URB597; (2) a smaller delayed and long‐lasting increase, not sensitive to CB1, VR1or FAAH blockade. Both effects were blocked by infusing either tetrodotoxin (TTX, 1 µm) or calcium‐free Ringer's solution through the microdialysis probe, demonstrating that they were dependent on the physiologic activation of dopaminergic neurotransmission. Thus, these results indicate that anandamide, through the activation of the mesolimbic dopaminergic system, participates in the signaling of brain reward processes.

1 September 2003 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
ZJZuzana Justinova
Zuzana Justinova
GTGianluigi Tanda
Gianluigi Tanda
GRGodfrey H. Redhi
Godfrey H. Redhi
SGSteven R. Goldberg
Steven R. Goldberg

20 January 2003 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
MKMarzena Karcz-Kubicha
Marzena Karcz-Kubicha
KAKaterina Antoniou
Katerina Antoniou
ATAnton Terasmaa
Anton Terasmaa
DQDavide Quarta
Davide Quarta
MSMarcello Solinas
Marcello Solinas
SFSergi Ferre
Sergi Ferre

1 August 2008 in Neuropharmacology
Verified
Journal Article
Closed access
CFCarla Ferrada
Carla Ferrada
SFSergi Ferre
Sergi Ferre
VCVicent Casadó
Vicent Casadó
ACAntonio Cortés
Antonio Cortés
ZJZuzana Justinova
Zuzana Justinova
Rafael FrancoRafael Franco
Rafael Franco

1 December 2008 in Biological Psychiatry
Verified
Journal Article
Open access
ZJZuzana Justinova
Zuzana Justinova
RMRegina Mangieri
Regina Mangieri
Marco BortolatoMarco Bortolato
Marco Bortolato
SCSvetlana I. Chefer
Svetlana I. Chefer
AMAlexey G. Mukhin
Alexey G. Mukhin
SGSteven R. Goldberg
Steven R. Goldberg
CB(1) cannabinoid receptors in the brain are known to participate in the regulation of reward-based behaviors. However, the contribution of each of the endocannabinoid transmitters, anandamide and 2-arachidonoylglycerol (2-AG), to these behaviors remains undefined. To address this question, we assessed the effects of URB597, a selective anandamide deactivation inhibitor, as a reinforcer of drug-seeking and drug-taking behavior in squirrel monkeys. We investigated the reinforcing effects of the fatty acid amide hydrolase (FAAH) inhibitor URB597 in monkeys trained to intravenously self-administer Delta(9)-tetrahydrocannabinol (THC), anandamide, or cocaine and quantified brain endocannabinoid levels using liquid chromatography/mass spectrometry. We measured brain FAAH activity using an ex vivo enzyme assay. URB597 (.3 mg/kg, intravenous) blocked FAAH activity and increased anandamide levels throughout the monkey brain. This effect was accompanied by a marked compensatory decrease in 2-AG levels. Monkeys did not self-administer URB597, and the drug did not promote reinstatement of extinguished drug-seeking behavior previously maintained by THC, anandamide, or cocaine. Pretreatment with URB597 did not modify self-administration of THC or cocaine, even though, as expected, it significantly potentiated anandamide self-administration. In the monkey brain, the FAAH inhibitor URB597 increases anandamide levels while causing a compensatory down-regulation in 2-AG levels. These effects are accompanied by a striking lack of reinforcing properties, which distinguishes URB597 from direct-acting cannabinoid agonists such as THC. Our results reveal an unexpected functional heterogeneity within the endocannabinoid signaling system and suggest that FAAH inhibitors might be used therapeutically without risk of abuse or triggering of relapse to drug abuse.